Independent Policy Research · April 2026

Independent Policy Research on
Heartworm Prevention Access
and Prescribing Standards

This site presents independent, data-driven research on heartworm prevention access, clinical proportionality, and evidence-based prescribing standards. Our analysis examines the evidence base for current annual testing practices, the cost barriers they create for dog owners in high-prevalence regions, and the gap between FDA-approved label requirements and standard practice protocols. The goal is to inform evidence-based policy discussions among veterinary professionals, researchers, and public health advocates.

8
Major ML preventives reviewed — none require renewal testing on FDA label
~2,000
Tests needed to find one positive in a consistently-dosed compliant dog in a moderate-prevalence county
2005
Year the mandate originated — as an FDA surveillance request, not a clinical standard
$268K
Estimated cost to detect one positive in a compliant dog in a moderate-prevalence county (CAPC data + Atkins 2014)

The Issue

The evidence behind current testing practices

At most U.S. veterinary clinics today, a dog owner who wants to refill their pet's heartworm prevention medication — even after years of documented continuous use — must first pay for an annual antigen test and wellness visit before the prescription will be renewed. No exceptions. No waivers.

"The heartworm test is not a state-mandated legal requirement, but it is a strict veterinary requirement required to prescribe prevention. Technically, a doctor can [prescribe without it]."

— Tampa Bay area veterinary clinic staff member, March 2026

This research does not argue against heartworm testing. It examines the evidence base for mandatory annual testing as a precondition for renewing prevention prescriptions for established, compliant dogs — and asks whether the clinical data, cost implications, and guideline development process support that standard as currently applied.

Many veterinarians implement this mandate from genuine clinical concern — early detection, resistance mitigation, or liability pressure imposed by corporate ownership changes. This site does not question that motivation. It questions whether the evidence supports this mechanism, and whether the harm the mandate creates has ever been weighed against the benefits it claims.

The 2024 AHS guidelines state that "treating in the absence of diagnostics, while not ideal, is better than refusing to perform a needed treatment." If that principle holds — and it is difficult to reject without also rejecting triage medicine — then the corollary writes itself: dispensing prevention without a mandatory test is better than leaving a dog unprotected. An owner's access to monthly heartworm prevention should not be conditioned on an annual diagnostic test. Whether they decline it, cannot afford it, or simply exercise the informed refusal the AHS waiver framework was designed to accommodate — the dog should not go unprotected as a result.

— The Threshold Argument: if you accept this, the rest follows. See Executive Summary Section V of the White Paper.

The American Heartworm Society, the primary source of this standard, lists among its sponsors the manufacturers of both the ML preventive drugs the guidelines govern and IDEXX Laboratories, the manufacturer of the diagnostic test the guidelines recommend annually. Questions about guideline development transparency and the disclosure of sponsor relationships are examined in the full white paper.

FDA Label Review

A direct review of all 8 major FDA-approved ML preventive labels confirms: not one requires pre-administration testing at prescription renewal. All testing language is limited to initiation. Advantage Multi contains no testing language at all.

Primary Source

AHS Research Chair Tom Nelson DVM confirmed in March 2026 that the annual testing recommendation was introduced at the FDA's request for post-market surveillance — not as a patient safety determination. The geographic limitation was silently removed when AHS translated it into a national standard.

AHS Own Documents

For years before the current de facto mandate emerged, signed informed-consent waivers coexisted with AHS recommendations as standard practice. The AHS still publishes an official Heartworm Preventive Waiver template (© 2020) on its website today. The shift to waiver refusal is a recent institutional policy — not a discovery that waivers were always impermissible. No published research documents that the progressive hardening of AHS guideline language has produced, or is expected to produce, better clinical outcomes for individual compliant patients.

The Financial Alignment

Manufacturer satisfaction guarantees (up to $1,500 coverage) explicitly condition eligibility on annual negative testing. Owners who sign a waiver are waiving a financial warranty — not bypassing a clinical safeguard. This distinction is not disclosed at the point of care.

The Access Problem

CAPC's own published research (Wang et al., 2014 — 9 million tests) identifies income as a statistically significant predictor of heartworm prevalence. The states with the highest heartworm rates are also the poorest. No manufacturer, guideline body, or government program funds subsidized testing access in those areas. The mandate's cost falls hardest precisely where heartworm risk is greatest. Published research on the impact — or expected impact — of denying prevention access to patients who refuse or cannot afford this diagnostic test is absent from the literature.

Research & Projects

Active research program

Original data collection, policy analysis, and peer-reviewed submissions examining prevention access, cost barriers, and clinical proportionality.

Original Data · In Progress

Multi-State Clinic Practice Survey

Systematic audit of heartworm prevention prescribing policies across veterinary practices in FL, MS, TX, CA, and MN. Documents waiver acceptance rates, mandate language, and ownership structure. Current results: n=63; 51 of 63 practices (81%) require annual antigen testing, 11 accept a waiver, 1 reports it depends on the type of preventive. Waiver acceptance is higher among independent practices (8 of 11) than corporate (3 of 11).

Target: 150–250 responses · Rural/suburban segmentation · CAPC prevalence overlay

Policy White Paper · April 2026

The Annual Heartworm Testing Mandate: Clinical Evidence, Guideline Integrity, and Owner Autonomy

45+ page analysis integrating clinical, autonomy, and structural lines of argument. Includes CAPC-derived number-needed-to-screen analysis (how many tests are required to find one positive in a compliant dog), FDA label review, primary source confirmation from AHS Research Chair, and Mediterranean natural experiment data.

Download PDF →

Viewpoint Essay

When Professional Guidelines Contradict Themselves

Examines the internal contradiction between the AHS treatment principle — that care should not be withheld pending diagnostic completeness — and the operationalized testing mandate that withholds prevention when diagnostics are declined.

Public Health Essay

The Math Behind Mandatory Heartworm Testing Doesn't Add Up

First-person policy essay presenting the number-needed-to-screen analysis — how many tests must be performed to find one positive in a compliant dog — and the resulting cost-to-detect findings for a general health policy audience. Documents the access barrier argument using CAPC data and comparative screening thresholds from human medicine.

Proposed Study

LMRV Regional Access Study with Income Overlay

Proposed analysis linking CAPC county-level prevalence data with household income distributions and prevention access barriers across the Lower Mississippi River Valley — the region with the highest heartworm burden and lowest median household income in the U.S.

The Evidence

Three independent lines of analysis.
The same conclusion.

The clinical argument examines test reliability, residual infection risk, and proportionality. The autonomy argument examines prescribing authority and informed consent frameworks. The structural argument examines guideline origins, sponsor relationships, and the absence of transparency disclosures. Together they raise questions a professional standard of this scope should be able to answer.

🔬

The Clinical Case

The safety rationale fails at renewal for consistently-dosed, asymptomatic patients.

  • The renewal paradox: if slow-kill was underway, it was authorized by the prior prescription — the renewal test detects it retroactively, not preventively
  • ML-induced antigen suppression delays detectability to ~9 months — the test is least reliable in exactly the scenario it targets
  • Reach-back efficacy achieves ~95% worm burden reduction in compliant dogs — the biological event resolved months before month 12
  • CAPC data: positivity rates are consistently lowest in dogs with documented continuous prevention
  • The SNAP test and entire IDEXX confirmatory cascade cannot identify ML-resistant strains — the resistance-detection rationale cannot be fulfilled by the test being mandated
  • Adulticide (melarsomine) works against resistant and susceptible adult worms — a positive result doesn't change the treatment protocol
⚖️

The Autonomy Case

Veterinary prescribing authority was delegated to protect the individual patient — not to enforce population surveillance or manufacturer warranty terms.

  • Waiver-based prescribing coexisted with AHS recommendations as standard practice for years before the current de facto mandate emerged — the shift to waiver refusal is a recent institutional policy requiring its own justification
  • AHS guidelines are advisory, not statutory — no U.S. state practice act directly incorporates them as binding law
  • Waiver refusal appears driven by insurer risk calculus, not legal requirement — confirmed by clinic staff in Tampa Bay
  • Manufacturer warranty eligibility requires annual testing — owners signing waivers are waiving a financial guarantee, not a clinical safeguard
  • The rabies analogy fails: unlike statutory vaccine mandates, heartworm resistance tracking is an industry initiative without legislative standing
  • The AHS publishes an official Heartworm Preventive Waiver template — yet its 2024 guidelines say prescribing without testing is "NOT RECOMMENDED" — a contradiction the AHS has not resolved
🔗

The Structural Case

The guideline origin is post-market surveillance, not individual patient safety — and the progressive hardening of the standard over two decades lacks a published evidence basis in improved patient outcomes.

  • Testing mandate originated as an FDA post-market surveillance request (confirmed: Tom Nelson DVM, AHS Research Chair, March 2026) — not a patient safety determination
  • AHS guideline language hardened progressively: 2005 recommendation → 2014 stronger language → 2024 explicit "NOT RECOMMENDED" — with no published research demonstrating that stricter language improves outcomes for compliant individual patients
  • No equivalent mandatory pre-prescription testing exists in any EU heartworm-endemic country, including Mediterranean nations with year-round transmission
  • Canary Islands (Spain): canine heartworm prevalence fell from 67% (1994) to 15.8% (2020) under OTC-access model without mandatory testing — Montoya-Alonso et al., 2024
  • First ML-resistant case in Europe (2024) was a dog imported from the U.S. — not generated by the European OTC framework — Ciuca et al., 2024

The Numbers

What the mandate actually costs

Calculate what annual heartworm prevention costs for your dog — and what the mandatory visit requirement adds on top of it.

Annual Cost Calculator

Select your dog's size, preferred medication, and local pricing. See what the mandate adds above the cost of protection alone.

$65$150

Range $65–$150; national average per AVMA 2025. Actual price varies by region and practice type.

$35$75

Cited range $35–$75 (Sulik K. DVM, PetMD 2025). Default: confirmed real-world price including draw and materials.

Prevention Only
Heartgard Plus, 26–50 lbs (annual)
$151
Cost of protection — the medication itself
Prevention + Mandatory Visit
Prevention + antigen test + wellness exam
$421
$151 prevention + $56 test + $214 exam
The Mandate Tax
What the testing requirement adds annually
$270
+179% above prevention cost alone
Prevention
$151
With Mandate
$421

If an owner skips prevention due to this cost barrier and their dog contracts heartworm, treatment costs $600–$3,000+ — melarsomine injections, doxycycline, chest X-rays, 6–8 weeks crate rest. Severe caval syndrome cases: $3,000–$6,000.
Source: Sulik K. DVM, reviewed by Coates J. DVM, PetMD April 2025

Sources: Prevention prices: Chewy.com, 6-month supply × 2, March 2026 (standard retail). Antigen test: Sulik K. DVM, PetMD Apr. 2025 ($35–$75 range). Wellness exam: AVMA 2025 data via Pawlicy Advisor Dec. 2025. Treatment: PetMD Apr. 2025. This calculator is illustrative; individual prices vary by region and practice.

The Proportionality Problem

How does this mandate compare to other screening standards?

Condition Annual Risk / Incidence Mandatory Pre-Screening?
Canine vaccine adverse event ~0.194% (Moore et al., 2023) No
Breast cancer, women aged 40–74 ~0.14% average annual (USPSTF, 2024) Recommended every other year, not mandated
Heartworm, non-compliant dog (moderately endemic county) ~0.466% (CAPC, Pinellas County, April 2026) Yes — mandatory annual
Heartworm, compliant dog (moderately endemic county) ~0.05–0.2% adjusted Yes — mandatory annual

Risk estimates for compliant dogs are derived using CAPC county-level testing data (April 2026) and compliance-gap data from Atkins et al. (2014). These are approximations, not directly measured figures. See the white paper Section 2.6 for full methodology.

Take Action

What you can do right now

You have more options than you may have been told. Here's what to know before your next vet visit.

01

Ask about the AHS Waiver

The American Heartworm Society publishes an official Heartworm Preventive Waiver template that any practice can use. It was designed for two kinds of situations: owners who have assessed the evidence and determined that annual testing is not proportionate to their dog's actual risk given consistent preventive use — and owners for whom the added cost of testing is a barrier that would leave their dog unprotected altogether. In either case, the waiver allows continued access to prevention with documented informed consent. Ask your veterinarian whether they will accept a signed waiver in lieu of annual testing.

Download the AHS Waiver PDF →
02

Ask about the manufacturer warranty

Major ML manufacturers (Boehringer Ingelheim, Elanco, Zoetis) offer satisfaction guarantees covering up to $1,500 in treatment costs if a dog on their product develops heartworm. These guarantees require annual negative testing. Ask your vet to explain this — it's rarely disclosed at the point of care.

See Section 3.7 of the White Paper →
03

Share this with your veterinarian

The white paper documents the clinical, autonomy, and structural analysis in full, with primary source citations. Many veterinarians are implementing standard practice policy. Sharing the evidence supports informed clinical conversations.

Download the White Paper →

Stay informed

This research initiative welcomes input from veterinary professionals, dog owners, policy researchers, and public health advocates interested in prevention access and clinical guideline development. If you have encountered cost-related barriers to heartworm prevention or have professional expertise relevant to this research, we welcome your perspective.

Your information is used only to follow up on this issue. It is never sold or shared.

No spam. Updates only when there is something meaningful to share.

Resources

For researchers, veterinary professionals,
and journalists

The full white paper documents every claim with primary source citations. Press inquiries welcome.

📄

Policy White Paper

The Annual Heartworm Testing Mandate: Clinical Evidence, Guideline Integrity, and Owner Autonomy

45+ Pages
7 Sections
Mar 2026 Updated Apr 2026

Three integrated lines of argument — clinical, autonomy-based, and structural — supported by FDA DailyMed label analysis, direct primary source correspondence with AHS Research Chair Tom Nelson DVM, AHS guideline review, manufacturer guarantee documentation, and CAPC prevalence data.

↓ Download White Paper (PDF)

Press Contact

For interview requests, background information, or to request primary source documentation:

[email protected]

HeartwormChoice.org
Tampa Bay, Florida

References

The white paper's References section documents every primary source cited in the analysis — FDA labels, AHS guidelines, CAPC data, peer-reviewed studies, and direct correspondence.

View in White Paper →